Related references
Note: Only part of the references are listed.Current multidisciplinary management of brain metastases
Michael J. Moravan et al.
CANCER (2020)
Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma
Takaaki Nakashima et al.
IN VIVO (2020)
Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers
Aaron C. Tan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
Kazuhiko Nakagawa et al.
LUNG CANCER (2020)
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Todd M. Bauer et al.
TARGETED ONCOLOGY (2020)
Economic burden in patients with ALK plus non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors
Huamao M. Lin et al.
JOURNAL OF MEDICAL ECONOMICS (2020)
Intracranial disease control forEGFR-mutant andALK-rearranged lung cancer with large volume or symptomatic brain metastases
Sunil W. Dutta et al.
JOURNAL OF NEURO-ONCOLOGY (2020)
ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3
G. Selvaggi et al.
Journal of Thoracic Oncology (2020)
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group
Paolo Borghetti et al.
RADIOLOGIA MEDICA (2019)
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Caicun Zhou et al.
LANCET RESPIRATORY MEDICINE (2019)
Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection A Secondary Analysis of a Randomized Clinical Trial
Thomas M. Churilla et al.
JAMA ONCOLOGY (2019)
Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study
S. Novello et al.
ANNALS OF ONCOLOGY (2018)
Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Leora Horn et al.
CLINICAL CANCER RESEARCH (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK plus ) non-small-cell lung cancer: CNS efficacy results from the ALEX study
S. Gadgeel et al.
ANNALS OF ONCOLOGY (2018)
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Benjamin J. Solomon et al.
LANCET ONCOLOGY (2018)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Dong-Wan Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Updated Efficacy and Safety Results From ALTA, a Randomized Phase 2 Trial
M. Ahn et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria et al.
LANCET (2017)
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice T. Shaw et al.
LANCET ONCOLOGY (2017)
Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
Solange Peters et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases
Pablo Martinez et al.
JAMA ONCOLOGY (2017)
The Diminishing Role of Whole-Brain Radiation Therapy in the Treatment of Brain Metastases
Jing Li et al.
JAMA ONCOLOGY (2017)
Estimating Survival in Patients With Lung Cancer and Brain Metastases An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto et al.
JAMA ONCOLOGY (2017)
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer
Solange Peters et al.
CANCER TREATMENT REVIEWS (2016)
Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases
William J. Magnuson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis
Kimberly L. Johung et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer
Shirish M. Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 4.2016 Featured Updates to the NCCN Guidelines
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2016)
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim et al.
LANCET ONCOLOGY (2016)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Daniel B. Costa et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Isabella Zhang et al.
LANCET ONCOLOGY (2015)
Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases
Tatsushi Kodama et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial
Vinai Gondi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
Ted W. Johnson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Shirish M. Gadgeel et al.
LANCET ONCOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
Puey Ling Chia et al.
CLINICAL EPIDEMIOLOGY (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of Brain Metastases in Lung Cancer: Strategies to Avoid/Reduce Late Complications of Whole Brain Radiation Therapy
Mark G. Shaw et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
Takashi Seto et al.
LANCET ONCOLOGY (2013)
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
F. Barlesi et al.
ANNALS OF ONCOLOGY (2011)
Three Cheers for Targeted Therapy in Non-Small Cell Lung Cancer ... When We Hit The Target!
G. Codacci-Pisanelli et al.
JOURNAL OF CHEMOTHERAPY (2011)
The biology of brain metastases-translation to new therapies
April F. Eichler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
Eric L. Chang et al.
LANCET ONCOLOGY (2009)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases - A randomized controlled trial
Hidefumi Aoyama et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Multidrug resistance in brain tumors: Roles of the blood-brain barrier
A Regina et al.
CANCER AND METASTASIS REVIEWS (2001)
Share Paper
